Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05019716RecruitingPhase 1/Phase 2
Adding ZEN003694 to chemo for NUT cancer
This early-phase study tests whether adding ZEN003694 to standard chemotherapy (cisplatin/etoposide or carboplatin/paclitaxel) is safe and can help control NUT carcinoma. It enrolls people ages 12–17 and adults, including some patients whose cancer has spread or can’t be safely removed.
Los Angeles, CaliforniaAges 12 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
La Jolla, CaliforniaAges 12 years+ - NCT04975152RecruitingPhase 1
Cemiplimab before surgery for Merkel cell and skin cancers
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
Tampa, FloridaAges 18 years+ - NCT04878029RecruitingPhase 1
Cabozantinib plus enfortumab for advanced bladder cancer after immunotherapy
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT04575935RecruitingPhase 3
Minimally invasive surgery after chemotherapy for advanced ovarian cancer
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Miami, FloridaAges 18 years+ - NCT04564989Recruiting
Biomarker study for HPV-related throat cancer outcomes
This observational study checks how well a blood test for HPV DNA (and other tumor genetic markers) predicts outcomes in certain throat cancers. It may help doctors better track the disease and plan treatment, because the trial validates these lab signals against real-world results.
Rochester, MinnesotaAges 18 years+ - NCT04410302Recruiting
Personalized tumor research for bladder, lung, stomach, and liver cancers
This study uses a small sample of your tumor to grow it in the lab, which may help researchers understand your cancer better and find treatments that work for you.
Orange, CaliforniaAges 21–100 - NCT04469764RecruitingPhase 2
Abemaciclib for certain recurrent ovarian or endometrial cancers
This Phase 2 study tests abemaciclib, a targeted pill treatment, for recurrent ovarian or endometrial cancer that shows specific tumor genetic patterns. It may help slow or control cancer growth in people whose tumor matches the required test results.
Los Angeles, CaliforniaAges Any age - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT04834544RecruitingPhase 2
Maintenance vaccine treatment after first chemotherapy for ovarian cancer
This Phase 2 trial studies a maintenance vaccine (DCVAC/OvCa) given after standard first-line chemotherapy and surgery for certain advanced ovarian cancers. It aims to help keep the cancer from coming back for longer by boosting the body’s anti-cancer response.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05157763RecruitingPhase 1/Phase 2
Test ointment for small basal cell skin cancers
This Phase 1/2 trial tests EscharEx (an investigational treatment) to see if it is safe and works on a single small basal cell skin cancer on the trunk or upper arms. You might qualify if your cancer fits specific size and location rules and you have not had radiation to that spot.
Aventura, FloridaAges 18 years+ - NCT05252078RecruitingPhase 2
Anlotinib plus an injection after esophageal cancer surgery
This Phase 2 study tests whether anlotinib tablets combined with an injection (TQB2450) can lower the risk of esophageal squamous cell cancer coming back after surgery. It may help by targeting cancer growth signals and blood-vessel formation to reduce recurrence.
Nanchang, JiangxiAges 18 years+ - NCT05693116Recruiting
Study factors that affect outcomes in nasal vestibule cancer
This study looks at survival and outcome factors for people who have squamous cell carcinoma in the nasal vestibule. It uses information from surgery and scans and checks tissue samples to see what predicts recovery or risk of problems later.
Toulouse, TouluseAges 18 years+ - NCT06167356Recruiting
Bladder cancer relapse and quality of life study after TURBT
This study tracks patients with early-stage bladder cancer after surgery (TURBT) to see how often the cancer returns and how it affects your daily life.
Milan, MIAges 18 years+ - NCT06170177Recruiting
Life after bladder removal surgery study
This study looks at how people feel and their health after having their bladder removed. It aims to understand quality of life after this surgery.
Milan, MIAges 18 years+ - NCT04894370RecruitingPhase 2
Trial tests immunotherapy plus chemotherapy and radiation for anal cancer
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
BesançonAges 18 years+ - NCT04716686RecruitingPhase 2
Niraparib alone to help prevent cancer coming back
This Phase 2 study tests niraparib by itself to keep endometrial serous cancer from returning or to control it after chemotherapy helps. It may help some people by targeting tumor DNA repair weaknesses, especially in cancers with certain gene changes.
Jinan, ShandongAges 18 years+ - NCT06211790RecruitingPhase 2
Targeted first-line treatment for advanced kidney cancer based on protein profile
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
ShanghaiAges 18–75 - NCT07869836RecruitingPhase 3
Comparing new drug to standard chemo for advanced bladder cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
Macon, GeorgiaAges 18 years+ - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT07815665RecruitingPhase 2/Phase 3
Ivonescimab plus enfortumab vedotin for advanced bladder cancer
This study compares two drug combinations for advanced bladder cancer that has spread or cannot be removed with surgery. The drugs aim to help the immune system fight the cancer more effectively.
Phoenix, ArizonaAges 18 years+ - NCT07748988RecruitingPhase 1
Casdatifan for advanced kidney cancer that has stopped responding
This study tests a new pill called casdatifan for people with advanced kidney cancer that has not improved after standard treatments. The goal is to see if the drug can shrink tumors and be safe to take.
Nashville, TennesseeAges 18–100 - NCT05797415Recruiting
Check sentinel lymph node biopsy for several eye skin cancers
This trial studies whether a “sentinel lymph node biopsy” can better detect cancer spread in people with specific cancers of the eye surface and nearby tissues. It may help doctors find the right next treatment by learning whether lymph nodes are involved.
Roma, RomeAges 18–95
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,117 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.